Charcot Marie Tooth disease (CMT) is the eponym for heritable peripheral neuropathy. CMT affects approximately 1 in 2500 people and is divisible into three large sub-groups;CMT1 (dominantly inherited demyelinating neuropathies), CMT2 (dominantly inherited axonal neuropathies), and CMT4 (recessively inherited neuropathies). Mutations in more than 70 genes cause CMT1, CMT2 and CMT4. The biological basis for demyelination and axonal degeneration in these disorders has enabled rational therapy development for some kinds of CMT. Clinical trials, however, have been limited by a combination of a lack of natural history data, a lack of outcome measures that are sensitive to change in a short period, and a lack of outcome measures for young children with CMT. We have enrolled over 4200 patients into the protocols of the Inherited Neuropathy Consortium (INC) during our first cycle in the RDCRN. Support from our patient advocacy groups (PAGs) has allowed us to expand from 6 to 15 sites within the INC. Additional support from NINDS allowed us to develop the CMT-lnternational Database (CMT-ID), a group of national CMT registries who also use the CMT Minimal Dataset and house their data at the DMCC. Taking these together, we have a unique opportunity to obtain and evaluate patients with rare forms of inherited neuropathy. We propose to extend our work over the next 5 years with the following Specific Aims:
Aim 1 : Expand natural history investigations on CMT1A, CMT1B, CMT1X and CMT2A.
Aim 2 : Accrue and evaluate patients with rare forms of CMT.
Aim 3 : Validate and test patient reported disability and QOL instruments in adults with CMT.
Aim 4 : Validate infant-toddler disability and QOL instruments in children with CMT.
TO THE INC RDCRC Developing outcome instruments that measure disease progression in a manner that is relevant to people afflicted with inherited peripheral neuropathies is one of the main goals of the Inherited Neuropathy Consortium (INC). Because these disorders are rare these studies can only be performed in a consortium of trained expert clinical investigators such as those in the INC.
|Rebelo, Adriana P; Abrams, Alexander J; Cottenie, Ellen et al. (2016) Cryptic Amyloidogenic Elements in the 3' UTRs of Neurofilament Genes Trigger Axonal Neuropathy. Am J Hum Genet 98:597-614|
|Rossor, Alexander M; Tomaselli, Pedro J; Reilly, Mary M (2016) Recent advances in the genetic neuropathies. Curr Opin Neurol 29:537-48|
|Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66|
|Auer-Grumbach, Michaela; Toegel, Stefan; SchabhÃ¼ttl, Maria et al. (2016) Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. Am J Hum Genet 99:607-23|
|Hu, Bo; Arpag, Sezgi; Zuchner, Stephan et al. (2016) A novel missense mutation of CMT2P alters transcription machinery. Ann Neurol 80:834-845|
|Lunn, Michael P; Ellis, Lauren; Hadden, Robert D et al. (2016) A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 21:33-7|
|Mademan, InÃ¨s; Harmuth, Florian; Giordano, Ilaria et al. (2016) Multisystemic SYNE1 ataxia: confirming the high frequency and extending the mutational and phenotypic spectrum. Brain 139:e46|
|Begg, Lindy; McLaughlin, Patrick; Vicaretti, Mauro et al. (2016) Total contact cast wall load in patients with a plantar forefoot ulcer and diabetes. J Foot Ankle Res 9:2|
|Manole, Andreea; Chelban, Viorica; Haridy, Nourelhoda A et al. (2016) Severe axonal neuropathy is a late manifestation of SPG11. J Neurol 263:2278-2286|
|Motley, William W; Palaima, Paulius; Yum, Sabrina W et al. (2016) De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease. Brain 139:1649-56|
Showing the most recent 10 out of 136 publications